Vnitr Lek 2006, 52(3):271-273
Extension of QT interval as a consequence of risk factor accumulation - case study
- 1 Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC
- 2 Oddělení lékařské genetiky FN Brno, pracoviště FDN J. G. Mendela, přednostka prim. MUDr. Renata Gaillyová
- 3 Katedra genetiky a molekulární biologie Přírodovědecké fakulty MU Brno, přednosta prof. RNDr. Jiří Doškař, CSc.
Background:
Many non-cardiovascular drugs have a potential for QT interval prolongation. This phenomenon can be related to occurence of ventricular tachycardia torsades de pointes, syncopi and even sudden death. Description of the case: A female patient treated with antracycline cytostatics developed a depression of left ventricle ejection fraction. At the same time she was administered 2 common drugs with proarrhythmic potential - terfenadine and itraconazole. In this patient hypokalemia also occured. Combination of the above mentioned risk factors led to QT interval prolongation and frequent ventricular tachycardias torsades de pointes degenerating in ventricular fibrillations with need of repeated defibrillations. Both drugs were withdrawn and dysiontaemia corrected. Then arrhythmias disappeared and QT interval completely normalized. In this patient the congenital long QT syndrome was not proved.
Discussion and conclusions:
In proarrhythmic effect of non-cardiovascular drugs the following factors play role: predisposition of a particular individual, "repolarization reserve", interindividual differences in drug metabolism. The risk factors are age, sex, dysiontaemia, heart disease and drug interactions. By different choice of medication and attention to risk factors teh life threat to the described patient could have been avoided.
Keywords: proarrhythmia; QT interval prolongation; sudden death
Received: October 5, 2005; Accepted: December 14, 2005; Published: March 1, 2006 Show citation
References
- Anderson ME, Al-Khatib SM, Roden DM et al. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 2002; 144: 769-781.
Go to original source...
Go to PubMed...
- Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets and side effects. N Engl J Med 2003; 348: 538-549.
Go to original source...
Go to PubMed...
- Fenichel RR, Malik M, Antzelevitch C et al. Independent Academic Task Force. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15: 475-495.
Go to original source...
Go to PubMed...
- Novotný T. Proarytmické účinky nekardiálních léků na podkladě prodloužení intervalu QT. Kardiol Prax 2004; 2: 119-122.
- Novotný T, Kadlecová J, Papoušek I et al. Mutační analýza LQT genů u jedinců s polékovým prodloužením QT intervalu. Vnitř Lék 2006; 52: (rukopis).
- Priori SP, Rivolta I, Napolitano C. Genetics of long QT, Brugada, and other channelopathies. In: Zipes DP, Jalife J. (eds). Cardiac electrophysiology: from cell to bedside. 4th ed. Philadelphia: WB Saunders 2004: 462-470.
Go to original source...
- Romano C, Gemme G, Pongiglione R. Aritmie rare dell'eta pediatrica. Clin Pediatr (Bologna) 1963; 45: 656-683.
Go to PubMed...
- Semrád B. Od selhání antiarytmik k pochopení fenoménu proarytmie. Vnitř Lék 2003; 49: 700-706.
Go to PubMed...
- Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-537.
Go to original source...
Go to PubMed...
- Zareba W, Lin AD. Antipsychotic drugs and QT interval prolongation. Psychiatr Q 2003; 74: 291-306.
Go to original source...
Go to PubMed...